AYOXXA to develop multiplex immunoassay to support treatment of sepsis patients

Apr 20 2018

AYOXXA Biosystems GmbH, an international biotechnology company, will develop a multiplex assay to support the treatment of sepsis patients as part of the project "SepsisData.Net.NRW - Digitized Pattern Recognition for Personalized Treatment of Sepsis Patients". The development will be based on the Company’s innovative bead-based protein analysis platform LUNARIS™.

As a result of the research project, the multiplex assay will be available as a commercial detection kit. It will be marketed initially for use in academic and preclinical research and, after further validation, for routine use in the clinic in the medium term.

The project is funded by the "European Regional Development Fund" (ERDF) and comprises a consortium of North Rhine-Westphalian companies, university hospitals and universities. Head of the project is Prof. Michael Adamzik from the Ruhr University Bochum and the University Hospital Bochum, Department of Anesthesiology, Intensive Care and Pain Therapy. The duration of the project is set for three years.